Pantić, Nikola (57221630977)Nikola (57221630977)PantićStojiljković, Milica (55217486100)Milica (55217486100)StojiljkovićGrujičić, Lenka (59909503300)Lenka (59909503300)GrujičićŠaranović, Dragana Šobić (57234390300)Dragana Šobić (57234390300)ŠaranovićArtiko, Vera (55887737000)Vera (55887737000)Artiko2025-06-122025-06-122025https://doi.org/10.2298/SARH241111031Phttps://www.scopus.com/inward/record.uri?eid=2-s2.0-105005894142&doi=10.2298%2fSARH241111031P&partnerID=40&md5=8a1049d8e59b8d7f49bdbc02cf64a1ebhttps://remedy.med.bg.ac.rs/handle/123456789/612Introduction The incidence of a second cancer among patients who have been treated for Hodgkin lymphoma (HL) is higher than the incidence of cancer in the general population.18F-fluorodeoxyglucose (18F-FDG) positron emission tomography / computed tomography is used in the evaluation of a number of malignancies. The aim of the article is to emphasize the importance of including a second primary cancer as a differential diagnosis among patients at risk. Case outline We present a case of a patient diagnosed with two separate malignancies almost two decades after the treatment of HL. Conclusion In patients previously treated for HL, a biopsy of lesions that show high 18F-FDG uptake should be advised, particularly if the location of the lesion is unusual for the primary diagnosis. © 2025, Serbia Medical Society. All rights reserved.chemo-therapylymphoma, Hodgkinpositron emission tomographyradiation therapysecond primary malignancy